ACCEL-DAPAGLIFLOZIN DIN 02543184
Health Canada record
| Active ingredient(s) | DAPAGLIFLOZIN 5 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | A10BK01 DAPAGLIFLOZIN |
| Original market date | 05-Jan-2026 |
| Current status date | 05-Jan-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Accel Pharma Inc — licence 101722, currently licensed, last inspection rating C (2025-07-07).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DAPAGLIFLOZIN
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02543192 | ACCEL-DAPAGLIFLOZIN | ACCEL PHARMA INC | Tablet | DAPAGLIFLOZIN 10 MG | Marketed |
| 02533057 | AG-DAPAGLIFLOZIN | ANGITA PHARMA INC. | Tablet | DAPAGLIFLOZIN 10 MG | Marketed |
| 02533049 | AG-DAPAGLIFLOZIN | ANGITA PHARMA INC. | Tablet | DAPAGLIFLOZIN 5 MG | Marketed |
| 02527189 | APO-DAPAGLIFLOZIN | APOTEX INC | Tablet | DAPAGLIFLOZIN 5 MG | Marketed |
| 02527197 | APO-DAPAGLIFLOZIN | APOTEX INC | Tablet | DAPAGLIFLOZIN 10 MG | Marketed |
| 02536153 | APO-DAPAGLIFLOZIN-METFORMIN | APOTEX INC | Tablet | DAPAGLIFLOZIN 5 MG; METFORMIN HYDROCHLORIDE 850 MG | Marketed |
| 02536161 | APO-DAPAGLIFLOZIN-METFORMIN | APOTEX INC | Tablet | DAPAGLIFLOZIN 5 MG; METFORMIN HYDROCHLORIDE 1000 MG | Marketed |
| 02531402 | AURO-DAPAGLIFLOZIN | AURO PHARMA INC | Tablet | DAPAGLIFLOZIN 5 MG | Marketed |
| 02531410 | AURO-DAPAGLIFLOZIN | AURO PHARMA INC | Tablet | DAPAGLIFLOZIN 10 MG | Marketed |
| 02533081 | AURO-DAPAGLIFLOZIN / METFORMIN | AURO PHARMA INC | Tablet | DAPAGLIFLOZIN 5 MG; METFORMIN HYDROCHLORIDE 1000 MG | Marketed |
| 02533073 | AURO-DAPAGLIFLOZIN / METFORMIN | AURO PHARMA INC | Tablet | DAPAGLIFLOZIN 5 MG; METFORMIN HYDROCHLORIDE 850 MG | Marketed |
| 02561336 | DAPAGLIFLOZIN | SANIS HEALTH INC | Tablet | DAPAGLIFLOZIN 10 MG | Marketed |
| 02561328 | DAPAGLIFLOZIN | SANIS HEALTH INC | Tablet | DAPAGLIFLOZIN 5 MG | Marketed |
| 02519860 | GLN-DAPAGLIFLOZIN | GLENMARK PHARMACEUTICALS CANADA INC. | Tablet | DAPAGLIFLOZIN 10 MG | Marketed |
| 02519852 | GLN-DAPAGLIFLOZIN | GLENMARK PHARMACEUTICALS CANADA INC. | Tablet | DAPAGLIFLOZIN 5 MG | Marketed |
| 02531364 | JAMP DAPAGLIFLOZIN | JAMP PHARMA CORPORATION | Tablet | DAPAGLIFLOZIN 5 MG | Marketed |
| 02531372 | JAMP DAPAGLIFLOZIN | JAMP PHARMA CORPORATION | Tablet | DAPAGLIFLOZIN 10 MG | Marketed |
| 02535300 | M-DAPAGLIFLOZIN | MANTRA PHARMA INC | Tablet | DAPAGLIFLOZIN 10 MG | Marketed |
| 02535297 | M-DAPAGLIFLOZIN | MANTRA PHARMA INC | Tablet | DAPAGLIFLOZIN 5 MG | Marketed |
| 02559072 | MINT-DAPAGLIFLOZIN | MINT PHARMACEUTICALS INC | Tablet | DAPAGLIFLOZIN 10 MG | Approved |
| 02559064 | MINT-DAPAGLIFLOZIN | MINT PHARMACEUTICALS INC | Tablet | DAPAGLIFLOZIN 5 MG | Approved |
| 02560941 | NB-DAPAGLIFLOZIN | NB PHARMA INC. | Tablet | DAPAGLIFLOZIN 10 MG | Approved |
| 02560933 | NB-DAPAGLIFLOZIN | NB PHARMA INC. | Tablet | DAPAGLIFLOZIN 5 MG | Approved |
| 02538342 | NRA-DAPAGLIFLOZIN | NORA PHARMA INC | Tablet | DAPAGLIFLOZIN 10 MG | Marketed |
| 02538334 | NRA-DAPAGLIFLOZIN | NORA PHARMA INC | Tablet | DAPAGLIFLOZIN 5 MG | Marketed |
| 02531550 | PMS-DAPAGLIFLOZIN | PHARMASCIENCE INC | Tablet | DAPAGLIFLOZIN 5 MG | Marketed |
| 02531569 | PMS-DAPAGLIFLOZIN | PHARMASCIENCE INC | Tablet | DAPAGLIFLOZIN 10 MG | Marketed |
| 02537664 | PRO-DAPAGLIFLOZIN | PRO DOC LIMITEE | Tablet | DAPAGLIFLOZIN 10 MG | Marketed |
| 02537656 | PRO-DAPAGLIFLOZIN | PRO DOC LIMITEE | Tablet | DAPAGLIFLOZIN 5 MG | Marketed |
| 02528983 | RIVA-DAPAGLIFLOZIN | LABORATOIRE RIVA INC. | Tablet | DAPAGLIFLOZIN 10 MG | Marketed |
| 02528975 | RIVA-DAPAGLIFLOZIN | LABORATOIRE RIVA INC. | Tablet | DAPAGLIFLOZIN 5 MG | Marketed |
| 02518732 | SANDOZ DAPAGLIFLOZIN | SANDOZ CANADA INCORPORATED | Tablet | DAPAGLIFLOZIN 5 MG | Marketed |
| 02518740 | SANDOZ DAPAGLIFLOZIN | SANDOZ CANADA INCORPORATED | Tablet | DAPAGLIFLOZIN 10 MG | Marketed |
| 02520591 | TARO-DAPAGLIFLOZIN | TARO PHARMACEUTICALS INC | Tablet | DAPAGLIFLOZIN 5 MG | Approved |
| 02520605 | TARO-DAPAGLIFLOZIN | TARO PHARMACEUTICALS INC | Tablet | DAPAGLIFLOZIN 10 MG | Approved |
| 02523590 | TEVA-DAPAGLIFLOZIN | TEVA CANADA LIMITED | Tablet | DAPAGLIFLOZIN 5 MG | Approved |
| 02523604 | TEVA-DAPAGLIFLOZIN | TEVA CANADA LIMITED | Tablet | DAPAGLIFLOZIN 10 MG | Approved |
| 02535874 | NAT-DAPAGLIFLOZIN | NATCO PHARMA (CANADA) INC | Tablet | DAPAGLIFLOZIN 10 MG | Cancelled Pre Market |
| 02535866 | NAT-DAPAGLIFLOZIN | NATCO PHARMA (CANADA) INC | Tablet | DAPAGLIFLOZIN 5 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 32128 | 2023-11-17 | Abbreviated New Drug Submission (ANDS) |
International API supply for DAPAGLIFLOZIN
69 active FDA Drug Master Files.
Request a quote for ACCEL-DAPAGLIFLOZIN